Toxicity of tumor necrosis factor is synergistic with gamma-interferon and can be reduced with cyclooxygenase inhibitors.
In recent studies, we have demonstrated that recombinant human tumor necrosis factor (rH TNF), as a single agent, has only minimal therapeutic activity for the treatment of metastatic disease, but when combined with recombinant murine gamma-interferon (rM gamma-IFN), we observed significantly more therapeutic activity than when either agent was administered alone. However, this combination also resulted in increased toxicity. Thus, we undertook a systematic toxicologic study of rH TNF alone or in combination with rM gamma-IFN. Briefly, the toxicity was similar to the generalized Shwartzman's reaction seen during endotoxin shock, with multifocal microthrombi and ischemic necrosis as sequelae. Lesions were observed in the lungs, liver, gastrointestinal tract (preferentially in the duodenum and cecum), testes or uterus, and bone marrow. Our results suggest that TNF (either directly administered or induced in situ) and its induction of arachidonic acid metabolites form one element of toxicity in this model. This conclusion is supported by studies revealing that the toxicity of rH TNF in combination with rM gamma-IFN can be reduced by inhibitors of the cyclooxygenase/lipoxygenase pathway.
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D016861:Cyclooxygenase Inhibitors; D004357:Drug Synergism; D006023:Glycoproteins / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*; D006098:Granulocytes / Q000473:pathology; D006412:Hematopoietic Stem Cells / Q000473:pathology; D007213:Indomethacin / Q000627:therapeutic use; D007371:Interferon-gamma / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*; D007422:Intestines / Q000473:pathology; D016859:Lipoxygenase Inhibitors; D008099:Liver / Q000473:pathology; D008168:Lung / Q000473:pathology; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D009362:Neoplasm Metastasis; D011994:Recombinant Proteins / Q000627:therapeutic use / Q000633:toxicity; D013154:Spleen / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha
D016861:Cyclooxygenase Inhibitors; D006023:Glycoproteins; D016859:Lipoxygenase Inhibitors; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; D001241:Aspirin; D007213:Indomethacin